Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ProCertus BioPharm collaborators at the University of Wisconsin have commenced enrolling patients in a clinical trial aimed at determining if ProCertus’ product DermX can prevent radiodermatitis in post-surgical breast cancer patients receiving radiation therapy.
Subscribe to our email newsletter
The trial is being conducted under the direction of James Cleary and George Cannon at the University of Wisconsin Carbone Cancer Center (UWCCC).
ProCertus founder, chairman and chief scientific officer William Fahl said the company had worked closely with Cleary and Cannon to identify radiotherapy patient populations in which DermX, when approved, will significantly eliminate some of the side effects of the cancer therapy experience.
ProCertus CEO and Venture Investors MD Paul Weiss said the company has a novel approach to prevent radiodermatitis, and thereby improve the patient’s quality of life.